Gilead Sciences (NASDAQ:GILD) had its price objective upped by stock analysts at Wells Fargo & Co from $89.00 to $95.00 in a report issued on Thursday, July 26th, The Fly reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Wells Fargo & Co’s price objective indicates a potential upside of 23.81% from the stock’s previous close.
Several other research analysts also recently weighed in on the stock. Robert W. Baird downgraded shares of Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 price target for the company. in a research report on Thursday, July 26th. Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 price target for the company in a research report on Wednesday, July 18th. BidaskClub upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, July 10th. ValuEngine upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, July 3rd. Finally, Raymond James started coverage on shares of Gilead Sciences in a research note on Thursday, June 28th. They set a “strong-buy” rating and a $93.00 price objective for the company. Twelve analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. Gilead Sciences has an average rating of “Buy” and an average target price of $88.00.
Gilead Sciences opened at $76.73 on Thursday, according to Marketbeat Ratings. Gilead Sciences has a twelve month low of $64.27 and a twelve month high of $89.54. The company has a debt-to-equity ratio of 1.23, a current ratio of 3.00 and a quick ratio of 3.23. The stock has a market cap of $101.17 billion, a P/E ratio of 11.23, a P/E/G ratio of -5.95 and a beta of 1.03.
In other news, Director John C. Martin sold 50,000 shares of the stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $70.81, for a total value of $3,540,500.00. Following the completion of the sale, the director now owns 3,067,762 shares of the company’s stock, valued at approximately $217,228,227.22. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last three months, insiders sold 150,000 shares of company stock valued at $10,839,500. Corporate insiders own 1.30% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Archford Capital Strategies LLC purchased a new position in shares of Gilead Sciences during the 1st quarter worth approximately $106,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $132,000. Certified Advisory Corp purchased a new position in shares of Gilead Sciences during the 4th quarter worth approximately $133,000. Brand Asset Management Group Inc. purchased a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $139,000. Finally, Advisors Preferred LLC purchased a new position in shares of Gilead Sciences during the 1st quarter worth approximately $140,000. 77.59% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Story: Price to Earnings Ratio (PE)
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.